| ||
| Aduro BioTech's Clinical Results from CRS-207 Phase 1 Trial Presented at AACR ... Business Wire (press release) CRS-207 was evaluated in a Phase 1 trial in 17 subjects with cancers known to express mesothelin: mesothelioma, non-small-cell lung, pancreatic and ovarian. ... See all stories on this topic » |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment